key: cord-0756083-x95j7r4k
authors: Cabibbo, Giuseppe; Rizzo, Giacomo Emanuele Maria; Stornello, Caterina; Craxì, Antonio
title: SARS‐CoV‐2 infection in patients with a normal or abnormal liver
date: 2020-12-01
journal: J Viral Hepat
DOI: 10.1111/jvh.13440
sha: 979bb0529bb5a90ca53923d0c8e047291068f6bf
doc_id: 756083
cord_uid: x95j7r4k

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel coronavirus causing coronavirus disease 19 (COVID‐19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS‐CoV‐2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID‐19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS‐CoV‐2 infection in patients with underlying chronic liver disease, a cohort whose global size is difficult to estimate, has been assessed appropriately only recently and data are still evolving. Patients with cirrhosis are at higher risk of developing severe COVID‐19 and worse liver‐related outcomes as compared to those with non‐cirrhotic liver disease. OLT patients have an intermediate risk. Specific interventions in order to reduce the risk of transmission of infection among this high‐risk population have been outlined by international societies, together with recommendations for modified treatment and follow‐up regimens during the COVID‐19 pandemic. When a vaccine against SARS‐CoV‐2 becomes available, patients with fibrotic liver disease and those with OLT should be considered as prime targets for prophylaxis of COVID‐19, as all other highly susceptible subjects.

have been reported according to the Center for Systems Science and Engineering (CSSE) at John Hopkins University, mostly in United States, Brazil and Russia, causing totally around 800,000 deaths. 2 In order to track seroprevalence estimates, it has also been developed a custom-built dashboard, which systematically monitors and synthesizes findings from hundreds of global SARS-CoV-2 serological studies. 3 A growing number of patients with COVID-19 continue to succumb worldwide, mostly due to respiratory complications but also showing impairment of other organ systems, including the liver.

During the early phase of the pandemic, most case series reporting liver damage did not make a clear distinction between subjects infected by SARS-CoV-2 and a previously normal liver and those in whom the infection occurred in the setting of a pre-existing liver disease. Even less information was available on the stage of liver disease (ie non-fibrotic vs fibrotic: compensated vs decompensated), which may be of major importance since patients with cirrhosis are often fragile and may be immunocompromised. In fact, infections of all types are the major determinant of acute-on-chronic liver failure (ACLF), a leading cause of mortality in cirrhosis. 4 

SARS-CoV-2 infects cells through the angiotensin-converting enzyme 2 (ACE2) host cell receptor, which is mainly present on the alveolar cells (type 2). 5 Crystallization of the SARS-CoV-2 RBD (receptor-binding domain)-ACE2 complex was achieved as soon as possible to understand the structural basis of ACE2 recognition by SARS-CoV-2. The spike (S) protein of coronaviruses facilitates viral entry into target cells and it may also be a target for future therapies. Shang et al illustrated the crystal structure of the RBD of the engineered spike protein of SARS-CoV-2 in complex with ACE2. 6 Interestingly, ACE2 expression is abundant in lung, heart, ileum, kidney, bladder, gastrointestinal tract and liver. 7 ACE2 receptors at the enterocyte level (glandular cells of gastric, duodenal and distal enterocytes) may explain gastrointestinal involvement, resulting usually in malabsorption, unbalanced intestinal secretion and activated enteric nervous system. 8 12 As mentioned above, liver involvement is documented as well, with hepatic dysfunction in severe cases.

Severe acute liver injury has been reported with higher mortality. 13 In fact, liver damage mainly arose with a pattern of elevated serum liver biochemistries in hospitalized patients with COVID-19 (primarily elevated AST and ALT, and slightly elevated bilirubin), ranging from 14% to 53%. Interestingly, it occurs more commonly in more severe COVID-19 cases than in mild cases. 14 Recently, a retrospective cohort study of 1827 patients within the Yale-New Haven Health System (YNHHS) confirmed a higher probability of severe infection in patients with increased age, male gender, higher BMI and abnormal liver tests. Moreover, liver injury was predominantly hepatocellular rather than cholestatic, and these patients had liver abnormalities both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, TBIL 16.1%). In this report, a multivariate analysis revealed the association between admission and peak hospitalization liver tests and clinical outcomes (ICU admission, mechanical ventilation, and death).

According to these data, patients with abnormal AST at admission have a higher risk of mechanical ventilation (OR 3.09, P < 0.001), as are those with abnormal AST, ALT and ALP at peak hospitalization (OR 5.87, 2.70 and 3.76, respectively). A subset of patients experienced liver transaminases > 5× ULN during hospitalization (AST 16 .6%, ALT 20.6%). Among them medications used in COVID-19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir and Bullet points:

• Patients with SARS-CoV-2 infection and no previous liver disease may develop mild-to-moderate liver injury, proportional to the severity of COVID-19.

• Patient with cirrhosis, and to a lesser degree those with OLT, when infected with SARS-CoV-2 have a high risk of death.

• The prevalence of chronic liver disease among patients with COVID-19 is undefined at a global level.

• Patients with chronic liver disease should be prioritized for immunization once a SARS-CoV-2 vaccine becomes available. tocilizumab) were associated with peak hospitalization aminotransferase elevations > 5× ULN. 15 Overall, data support a modest cytopathic acute liver damage by SARS-CoV-2 through a direct cytopathic effect, due to infection of hepatocytes mediated by the highly expressed ACE2 receptors.

Liver injury may also be caused by an uncontrolled immune response due to inflammatory activity, or as a consequence from therapies, manifesting as drug-induced liver injury (DILI). 16 Other evidence based on autopsies in patients who succumbed to COVID-19 supports the theory that macrovascular and microvascular thrombosis may play a predominant role in the pathophysiological pathway, determining hypoxic-ischaemic hepatic necrosis. 17 Another interesting hypothesis is that high levels of positive final expiratory pressure might cause hepatic congestion and hence abnormal liver blood tests, but data suggest that many hospitalized patients with COVID-19, even without mechanical ventilation, have similar biochemical abnormalities, dismissing this aetiology. 18 In any case, hepatocellular damage occurring in COVID-19 patients with an otherwise healthy liver rarely, if ever, causes acute liver failure.

COVID-19 studies initially focused on respiratory tract involvement, ignoring the effects of SARS-CoV-2 on organs such as liver or gut which were considered as secondarily impaired. At the beginning, a rapid short-time increase in publication data was motivated by the lack of knowledge against this sudden viral outbreak. For this reason, data quality was inevitably affected by the pressure to publish. Therefore, effects of COVID-19 on underlying well-defined chronic liver disease have been properly analysed only recently. Table 1 shows a summary of available data. A meta-analysis of 11 observational studies for a total of 20,134 adult individuals assessed a relatively low overall prevalence of chronic liver disease at baseline, being 3% (95% CI 2%-4%). 23 Some data on prevalence of liver disease can be extrapolated from a case series of 5,700 patients providing characteristics and early outcomes of patients hospitalized in New York City; 0.4% of the patients were known to be cirrhotic, 0.2% had a viral chronic liver disease, but no information was given about However, data about obesity, diabetes and metabolic disease were collected. It cannot be excluded that a great number of patients with early, ongoing liver involvement were underestimated, thus resulting in underrating of prevalence and outcomes. 24 Among studies conducted on cirrhotic patients, Qi et al 25 investigated the clinical course and risk factors for mortality in these affected patients. In fact, they provide a report on the demographic characteristics, comorbidities, laboratory and radiographic findings, and clinical outcomes in twenty-one SARS-CoV-2-infected patients with pre-existing cirrhosis. They finally concluded that the cause of death in most cases was due to respiratory failure rather than progression of liver disease such as development of acute-on-chronic liver failure. However, a multicentre retrospective study with a cohort of fifty cirrhotic patients gave interesting conclusions. The study aimed to evaluate the impact of COVID-19 on the clinical outcome of liver disease. It found a significant association between SARS-CoV-2 infection and liver decompensation; this being measured as higher scores both in Child-Pugh and MELD parameters. Consequently, COVID-19 was associated with elevated mortality, with a thirty-day rate of 34%, and that was independently predicted by CLIF-OF, CLIF-C, MELD and severity of lung failure. 26 Notably, Singh et al 27 obtained similar results among a much wider population of patients with chronic liver disease. They compared outcomes between those with and without pre-existing liver dysfunction; as expected, the former group experienced higher risk of hospitalizations and mortality, which were confirmed even after propensity score matching.

They hypothesized that poorer outcomes in cirrhotic patients may be attributed to many factors, such as an interplay of local liver injury and systemic disturbances, the expression of ACE2 receptors in liver and bile duct cells, medications and hypoxia. Table 2 shows the outcomes of COVID-19 patients with chronic liver disease. However, outcomes seem not to be excessively modified by current therapies, both in non-liver-injured and in liver-injured patients, probably because current medical management is largely supportive with no targeted therapy available. Several drugs including lopinavir-ritonavir, remdesivir, hydroxychloroquine and azithromycin have been tested in clinical trials, 28 but none of them have been proven to be a definite therapy yet. Convalescent plasma was routinely used for the treatment of critically ill COVID-19-infected patients when available, 29 even if it was shown to have no significant advantage in preventing mortality. 30 The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) showed that pre-existing liver disease is associated with a hepatic injury severe enough to cause liver failure in cirrhosis. These data were taken from 13 Asian countries and 62 investigators, with 228 CLD patients included 43 (18.9%) with cirrhosis (including 18 decompensated cirrhosis) and 185 (81.1%) without cirrhosis. More cirrhotic than non-cirrhotic patients had acute liver injury at admission (32.6% vs 20%, P < .001) and also developed new-onset liver injury in hospital (39.5% vs 7%, P < .001). 31 A large-scale collaborative registry project has been created to collect data on patients with liver disease at any stage or liver transplants who develop laboratory-confirmed COVID-19, both for patients who are hospitalized or managed in the community. The aim is to allow for analysis of baseline characteristics associated with specific outcomes in COVID-19 among those with liver disease. In the latest update, the total cohort include 957 patients, 88% of them being hospitalized and 63% of them being men. The median age was 59 years. Among these patients, 372 have chronic liver disease but 

It is important for medical staff to get acquainted with how to man- 

After the Chinese outbreak, Italy and Europe were significantly af- The current consensus is that SARS-CoV-2 infection will persist in the general population up to two years from now in the absence of active immunoprophylaxis. Hence, without a specific treatment, a vaccine is urgently required. 42 Because of the lack of aetiological therapies, vaccines are still considered the most promising way to eradicate SARS-CoV-2. 43 In conclusion, patients affected by cirrhosis should be considered as increased risk patients. Liver dysfunction that characterizes cirrhosis modifies the pathophysiology in many systems of the body; the management of these dysfunctions has been diligently improved over the years, but no effective recommendations have been given about clinical and logistical management of these patients during a pandemic. The outcomes in patients with cirrhosis with SARS-CoV-2 infection are strongly influenced by the susceptibility of these patients. Nevertheless, nobody has thought before this pandemic about how to manage access to clinical facilities in case of rigid restrictions, like those applied during lockdown. Therefore, this lack of adequate emergency programmes created a gap in the follow-up of chronic and susceptible patients in every medical field, as in hepatology. The delay in screening programmes of cancers and pathology complications may produce an increase in long-term mortality 52 because of many factors: loss in follow-up of low-compliance patients;

saturation of clinical capacity to reschedule examinations in shortterm; and difficulty to increase number of daily examinations due to COVID-regulations regarding distance and sanitization. Therefore, we strongly recommend stratifying patients when rescheduling screening examinations or monitoring suspicious complications in high-risk patients. Moreover, when the vaccine becomes available, we strongly suggest considering cirrhotic patients among those who need to be vaccinated first. National Health Organizations should generate protocols not only for the ongoing pandemic, but mainly for a second wave which may be even more severe than the first one, especially where the first wave is gone and SARS-CoV-2 is spreading at a slower rate. In that case, we recommend protecting cirrhotic patients considering them at high risk of death or complications, allowing them to access vaccination and care programmes as a priority. 

A novel coronavirus from patients with pneumonia in China

An interactive web-based dashboard to track COVID-19 in real time

Acute-on-chronic liver failure: getting ready for prime time?

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structural basis of receptor recognition by SARS-CoV-2

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus

COVID-19 and the liver

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

A major outbreak of severe acute respiratory syndrome in Hong Kong

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis

Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis

Liver injury in COVID-19: management and challenges

Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1827 patients in a major U.S. hospital network

COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

COVID-19 and the liver: little cause for concern

SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study

Review of trials currently testing treatment and prevention of COVID-19

Potential interventions for novel coronavirus in China: A systematic review

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement

Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy

Management of patients with autoimmune liver disease during COVID-19 pandemic

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Updated data from Italian Department of Civil Protection -Presidency of the Council of Ministers

The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care

Coast-to-coast spread of SARS-CoV-2 during the early epidemic in the United States

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

COVID-19: Facts and recommendations from A to

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Developing Covid-19 vaccines at pandemic speed

Nucleoside modified mRNA vaccines for infectious diseases

mRNA as novel technology for passive immunotherapy

An Evidence based perspective on mRNA-SARS-CoV-2 vaccine development

Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient

World Health Organization. Draft landscape of Covid-19 candidate vaccines

Safety and immunogenicity study of 2019-nCoV Vaccine (mRNA-1273) to prevent SARS-CoV-2 Infection

An mRNA Vaccine against SARS-CoV-2 -preliminary report

Screening of gastrointestinal cancers during COVID-19: a new emergency

SARS-CoV-2 infection in patients with a normal or abnormal liver